Interleukin-2 (IL-2) immunotherapy represents an emerging approach for Alzheimer's disease that targets the immune system rather than amyloid or tau directly. IL-2 is a cytokine that promotes the expansion and function of regulatory T cells (Tregs), which are key suppressors of neuroinflammation. A Phase II clinical trial (NCT06096090) is currently recruiting to evaluate the efficacy and safety of low-dose IL-2 in AD patients.
The rationale stems from the observation that Tregs are reduced in number and function in AD patients, leading to unchecked microglial activation, chronic neuroinflammation, and accelerated neurodegeneration. Restoring Treg populations through IL-2 administration may suppress pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and promote a more protective CNS environment.
¶ IL-2 Biology and Signaling
¶ IL-2 Structure and Function
Interleukin-2 is a 15.5 kDa cytokine originally characterized as a T cell growth factor. It is produced primarily by CD4+ T cells upon antigen activation and plays a central role in immune regulation:
- Lymphocyte proliferation: IL-2 drives clonal expansion of antigen-activated T cells
- Memory formation: Essential for maintaining long-lived memory T cell populations
- Immune homeostasis: Critical for Treg development and function
The IL-2 receptor exists in three affinity states:
| Receptor |
Composition |
Expression |
Response |
| Low-affinity |
CD122 (IL-2Rβ) |
Resting T cells, NK cells |
Minimal |
| Intermediate |
CD122 + CD132 |
Memory T cells |
Moderate |
| High-affinity |
CD25 (IL-2Rα) + CD122 + CD132 |
Tregs, activated T cells |
Strong |
Tregs express high levels of CD25 (the IL-2 receptor α-chain), giving them superior ability to capture IL-2 and maintain their population even when IL-2 is limiting.
IL-2 binding triggers canonical signaling cascades:
- JAK-STAT pathway: JAK1/JAK3 phosphorylate STAT5, driving Treg-specific gene expression
- PI3K-AKT pathway: Promotes cell survival and metabolic fitness
- MAPK pathway: Contributes to proliferation signals
Regulatory T cells (Tregs) are a specialized CD4+ T cell subset expressing FOXP3 transcription factor. They maintain immunological tolerance and prevent autoimmune responses:
- Suppressive mechanisms: CTLA-4, PD-1, IL-10, TGF-β, IL-35
- Metabolic disruption: CD25 expression outcompetes effector T cells for IL-2
- Trafficking: CCR4 and CXCR3 guide Tregs to sites of inflammation
Multiple studies document Treg abnormalities in Alzheimer's disease:
- Reduced numbers: AD patients exhibit 30-50% fewer circulating Tregs compared to age-matched controls
- Impaired function: Tregs from AD patients show reduced suppressive capacity in vitro
- FOP3 expression: Lower FOXP3 mRNA and protein in AD peripheral blood mononuclear cells
- Senescence: Increased Tregs show markers of cellular senescence (CD28−, CD57+)
Tregs protect the CNS through multiple mechanisms:
flowchart TD
A["IL-2 Administration"] --> B["Treg Expansion"]
B --> C["Increased CNS Trafficking"]
C --> D["Microglial Modulation"]
D --> E["Anti-inflammatory Cytokines"]
E --> F["IL-10, TGF-β Release"]
F --> G["M2 Microglial Phenotype"]
G --> H["Reduced Aβ Toxicity"]
G --> I["Synapse Protection"]
H --> J["Neuronal Survival"]
I --> J
¶ IL-2 and Tregs
IL-2 is the primary cytokine driving Treg proliferation and survival:
- Treg expansion: IL-2 binds the high-affinity IL-2 receptor (CD25/CD122/CD132) on Tregs, driving their clonal expansion
- Functional enhancement: IL-2 increases Treg suppressive capacity (CTLA-4, PD-1, IL-10 expression)
- Migration: Enhanced Tregs can traffic to the CNS and suppress microglial activation
Treg modulation by IL-2 reduces neuroinflammation through:
| Pathway |
Effect |
| Microglial suppression |
Tregs release IL-10, TGF-β → shift microglia from M1 to M2 phenotype |
| Cytokine reduction |
Decreased IL-1β, TNF-α, IL-6 in CNS parenchyma |
| Aβ clearance |
Improved microglial phagocytosis of amyloid plaques |
| Synapse protection |
Reduced complement-mediated synaptic pruning |
¶ Amyloid and Tau Interactions
Emerging evidence suggests Tregs influence amyloid and tau pathology:
- Amyloid clearance: Tregs promote microglial phagocytosis of Aβ through IL-10 signaling[@vom berg2020]
- Tau phosphorylation: Reduced pro-inflammatory cytokines decreases tau kinase activity
- Seeding propagation: Modulation of extracellular vesicle secretion may affect prion-like spread
NCT06096090 — Phase II Clinical Trial of Interleukin-2 in AD:
- Design: Randomized, double-blind, placebo-controlled
- Population: Patients with mild-to-moderate AD
- Intervention: Low-dose IL-2 (aldesleukin) subcutaneous administration
- Primary outcomes: Safety and tolerability; change in ADAS-Cog11 score
- Secondary outcomes: CSF biomarkers (p-tau, Aβ42), MRI brain volumes, Treg count
- Status: RECRUITING
Low-dose IL-2 (typically 1-2 million IU/m²) is used to preferentially expand Tregs over effector T cells:
- Low-dose rationale: Lower IL-2 doses preferentially support Treg survival due to their high CD25 expression
- Intermittent dosing: Weekly or biweekly administration to maintain Treg levels without causing effector T cell expansion
- Safety: Low-dose IL-2 has been safely used in thousands of oncology patients
Key studies supporting IL-2 in AD[@vom berg2020]:
- 5xFAD mice: IL-2 administration reduced amyloid burden, improved spatial memory, and increased Treg infiltration in the brain
- APP/PS1 mice: Intranasal IL-2 reduced plaque load and improved cognitive performance
- 3xTg-AD mice: Combination IL-2 with anti-amyloid antibody showed synergistic benefits
- Mechanism studies: Depletion of Tregs abrogated IL-2 benefits, confirming Treg dependence
Clinical observations supporting IL-2 therapy in AD:
- Treg deficiency: AD patients show reduced peripheral Tregs (~40% decrease vs. age-matched controls) and impaired Treg suppressive function
- IL-2 in CSF: Reduced IL-2 levels in cerebrospinal fluid of AD patients
- IL-2 in other diseases: Low-dose IL-2 is FDA-approved for melanoma and renal cell carcinoma; safe in elderly populations at low doses
Preliminary studies examining biomarker effects:
- CSF cytokines: IL-2 treatment may reduce CSF IL-1β and TNF-α
- PET imaging: TSPO PET signal reduction suggests decreased microglial activation
- Blood biomarkers: Treg count increases correlate with clinical benefits
| Aspect |
Assessment |
| Novelty |
First-in-class immunomodulation approach for AD |
| Mechanism |
Addresses neuroinflammation as a core disease driver |
| Target population |
Early-to-moderate AD patients with biomarker evidence of inflammation |
| Combination potential |
Synergistic with anti-amyloid, anti-tau, or symptomatic therapies |
| Safety profile |
Known from oncology; low doses minimize risk |
IL-2 represents a unique position in the AD immunotherapy landscape:
| Approach |
Target |
Mechanism |
Stage |
| IL-2 |
Tregs |
Expand anti-inflammatory cells |
Phase II |
| Anti-Aβ antibodies |
Amyloid plaques |
Clear existing plaques |
Approved |
| TREM2 agonists |
Microglia |
Enhance phagocytosis |
Phase II |
| CSF1R inhibitors |
Microglia |
Deplete pro-inflammatory microglia |
Phase II |
| Natalizumab |
T cells |
Prevent CNS infiltration |
Research |
¶ Adverse Events and Safety
Low-dose IL-2 is generally well-tolerated but may cause:
- Flu-like symptoms: Fever, chills, myalgia (common, transient)
- Injection site reactions: Redness, swelling at injection site
- Lymphocytosis: Expected increase in lymphocyte counts
- Mild capillary leak syndrome: Rare at low doses
¶ Contraindications and Precautions
- Autoimmune disease: May exacerbate existing autoimmune conditions
- Organ transplant: May increase risk of rejection
- Severe cardiac disease: Use with caution due to fluid shifts
Potential synergistic combinations:
- IL-2 + anti-amyloid antibodies: Coordinate plaque clearance with inflammation reduction
- IL-2 + anti-tau immunotherapy: Target both pathologies
- IL-2 + TREM2 agonists: Maximize microglial modulation
- IL-2 + symptomatic therapies: Maintain cognitive function while modifying disease
Key biomarkers for patient selection and response monitoring:
- Peripheral: Treg count, IL-10 levels, cytokine panels
- CSF: Neurofilament light chain, YKL-40, soluble TREM2
- Imaging: TSPO PET for microglial activation
Future directions include:
- Patient stratification: Identify patients with greatest Treg deficiency
- Dosing optimization: Individualize IL-2 dosing based on immune status
- Biomarker-driven: Use biomarker responses to guide treatment duration
Beyond Alzheimer's disease, Tregs play important roles in Parkinson's disease:
- Reduced Treg counts: PD patients show decreased circulating Tregs similar to AD
- Impaired function: Treg suppressive capacity is compromised in PD
- α-synuclein interactions: Tregs may influence α-synuclein aggregation and clearance
- Neuroinflammation: Chronic neuroinflammation drives dopaminergic neuron loss
IL-2 therapy may benefit PD through:
- Dopaminergic neuron protection: Reduced neuroinflammation preserves substantia nigra neurons
- α-synuclein modulation: Enhanced clearance of α-synuclein aggregates
- Microglial regulation: Shift from pro-inflammatory to protective phenotype
Tregs are also implicated in ALS:
- Treg deficiency: Reduced Tregs in ALS patients and mouse models
- Disease progression: Treg levels correlate with disease progression rate
- Therapeutic targeting: IL-2 expanding Tregs may slow motor neuron degeneration
IL-2 has been extensively studied in MS:
- Approved therapy: IL-2 is used clinically in MS (low-dose naltrexone connection)
- Treg enhancement: IL-2 preferentially expands Tregs in MS patients
- Relapse reduction: Clinical benefits observed in some patients
Emerging evidence suggests Tregs play roles in FTD:
- Immune dysregulation: FTD patients show abnormal Treg populations
- Neuroinflammation: TDP-43 pathology associates with microglial activation
- Therapeutic potential: IL-2 may modulate neuroinflammation in FTD
Tregs secrete multiple anti-inflammatory cytokines:
| Cytokine |
Mechanism |
Neuroprotective Effect |
| IL-10 |
Inhibits APC activation |
Reduces antigen presentation |
| TGF-β |
Suppresses effector T cells |
Decreases CNS inflammation |
| IL-35 |
Induces Treg conversion |
Expands suppressive pool |
Tregs also mediate suppression through direct contact:
- CTLA-4: Competes with CD80/CD86 on antigen-presenting cells
- PD-1: Engages PD-L1 on target cells to inhibit activation
- LAG-3: Binds MHC class II to suppress CD4+ T cells
Tregs outcompete effector cells for IL-2:
- High CD25: Tregs express high-affinity IL-2 receptor
- Metabolic advantage: Tregs have superior metabolic fitness
- Quorum sensing: Tregs sense and respond to local IL-2 concentrations
¶ Pharmacokinetics and Drug Delivery
Multiple IL-2 formulations exist:
| Formulation |
Brand Name |
Half-life |
Notes |
| Aldesleukin |
Proleukin |
85 min |
Short half-life |
| PEGylated IL-2 |
Pegylated |
48h |
Extended half-life |
| IL-2/Fc fusion |
Designer |
Variable |
Sustained release |
Different routes affect distribution:
- Subcutaneous: Standard route, good bioavailability
- Intravenous: Used in oncology, higher risk of side effects
- Intranasal: Direct CNS delivery, being explored for CNS diseases[@vom berg2020]
- Intrathecal: Experimental, targets CNS directly
IL-2 is a 15.5 kDa protein that does not readily cross the BBB:
- Peripheral mechanism: Primary effects through peripheral immune modulation
- Treg trafficking: Tregs can enter CNS through adaptive immune surveillance
- Transporters: Some IL-2 may enter via saturable transport systems
- Alternative routes: Intranasal delivery may bypass BBB
Key markers to assess before IL-2 therapy:
- Peripheral Treg count: Baseline Treg levels guide dosing
- Inflammatory cytokines: IL-1β, TNF-α, IL-6 indicate inflammation level
- Cognitive markers: Baseline ADAS-Cog, MMSE scores
- Imaging biomarkers: MRI volumes, PET amyloid/tau
Monitoring during treatment:
- Treg expansion: Serial Treg counts track treatment response
- Cytokine changes: Reduction in pro-inflammatory cytokines
- CSF biomarkers: Changes in p-tau, Aβ42, neurofilament light
- Imaging: MRI brain volume changes over time
Potential predictors of response:
- Treg responsiveness: Some patients respond better to IL-2
- Genetic markers: Polymorphisms in IL-2 and Treg-related genes
- Disease stage: Earlier intervention may be more effective
- Comorbidities: Age, other conditions affect response
¶ Competitive Landscape
Multiple approaches target Tregs in neurodegeneration:
| Approach |
Company |
Stage |
Mechanism |
| IL-2 |
Various |
Phase II |
Treg expansion |
| Low-dose IL-2 |
Various |
Research |
Treg selectivity |
| Anti-CD3 |
Research |
Preclinical |
Treg induction |
| Treg transfer |
Research |
Preclinical |
Adoptive transfer |
Rationale for combinations:
- Anti-amyloid + IL-2: Remove pathology + reduce inflammation
- Tau immunotherapy + IL-2: Target tau + modulate immunity
- TREM2 agonists + IL-2: Enhance microglia + expand Tregs
- CSF1R inhibitors + IL-2: Deplete bad microglia + expand Tregs
- AD prevalence: ~6 million in US, growing with aging population
- Unmet need: No disease-modifying therapies address neuroinflammation directly
- Competitive advantage: IL-2 has known safety profile from oncology
- Combination potential: Can be combined with other approaches
¶ Manufacturing and Clinical Considerations
- Recombinant expression: Produced in E. coli or mammalian cells
- Purification: Multiple chromatography steps required
- Formulation: Lyophilized or liquid formulations
- Stability: Store at 2-8°C, avoid freezing
Key elements for IL-2 trials in AD:
- Patient selection: Early-to-moderate AD, biomarker confirmation
- Dose optimization: Find lowest effective dose
- Duration: Determine optimal treatment length
- Endpoints: Cognitive, biomarker, imaging composite
- Fast track: Potential for accelerated approval based on biomarker endpoints
- Combination trials: May enable combination therapy approvals
- Biomarker-led: Biomarker-driven development strategies
- Orphan designations: Potential for rare neurodegenerative indications